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The predictive value of positron emission tomography
scanning performed after two courses of standard
therapy on treatment outcome in advanced stage
Hodgkin's disease
Several prognostic models have beenproposed over the last fifteen years forpatients affected by advanced-stage
Hodgkin’s disease (HD), with the aim of
defining risk-adapted therapeutic strategies.
In particular, various models based on a ret-
rospective reappraisal of the prognostic role
of different sets of clinical variables have
been proposed,1-4 but their predictive powers
have been questioned.5-7 Since 20-30% of
patients with advanced-stage HD treated
with conventional, standard-dose
chemotherapy ultimately die of recurrent of
refractory disease,8 the predictive value of an
early assessment of treatment response
seems to be very relevant. We report here,
on behalf of the Intergruppo Italiano Linfomi
(IIL), the results of a prospective clinical trial
aimed at exploring the prognostic role of
FDG-PET scanning performed very early
during therapy in hitherto untreated patients
with advanced stage HD undergoing con-
ventional, standard-dose chemotherapy. 
Design and Methods
Patients 
Starting in January 2002, 108 newly diag-
nosed patients with advanced-stage HD,
consecutively admitted to 11 Italian hema-
tology institutions were enrolled in the trial
and gave their written informed consent to
partecipation in this study. Their clinical
details are summarized in Table 1. Their
mean age was 32.6 years (range: 14-79) and
the male to female ratio was 51:57. Seventy-
four had advanced disease (stages IIB-IVB)
and 34 had stage IIA disease with adverse
prognostic factors (one of the following:
more than three nodal sites involved, sub-
diaphragmatic presentation, bulky disease
and erythrocyte sedimentation rate > 40
mm/h). Bulky and extra-nodal disease were
recorded in 41 and 30 patients, respectively.
Histopathology was lymphocyte predomi-
nant in four, nodular sclerosing in 88, mixed
cellularity in 13 and lymphocyte-depleted in
three. All patients were staged at baseline
with biochemistry, bone marrow trephine
biopsy, computed tomography (CT) scans,
and FDG-PET scans (PET-0). They were re-
staged after two chemotherapy courses and
at the end of the treatment, including radio-
therapy (when administered), by CT scans
and FDG-PET scans (CT-2, PET-2 and CT-6,
PET-6, respectively: Figure 1). Standardized
uptake values (SUV) were calculated in all
PET scans (see below). The end-point of the
study was the predictive value of PET-2 for
progression-free survival. The mean interval
between the end of the second chemothera-
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Background and Objectives. We explored the predictive value on therapy outcome of an
early evaluation of treatment response by 18F-fluorodeoxyglucose position emission tomog-
raphy (18F-FDG-PET) scan performed after two courses of conventional standard-dose
chemotherapy in advanced-stage Hodgkin’s disease.
Design and Methods. One hundred and eight patients with newly-diagnosed Hodgkin’s dis-
ease in stage IIA with adverse prognostic factors, or in stage IIB through IVB, were re-
staged with FDG-PET after two cycles of ABVD (PET-2). The end-point of the study was the
predictive value of PET-2 on 2-year progression-free survival and 2-year failure-free survival.
No treatment variation based only on PET-2 results was allowed. 
Results. Eighty-eight patients attained complete remission (CR) while 20 showed disease
progression during therapy or within 6 months after having reached CR; one patient
relapsed. PET-2 was positive in 20 patients: 17 progressed during therapy, one relapsed
and two remained in CR. By contrast, 85/88 (97%) patients with a negative PET-2
remained in CR; three progressed or relapsed early after the end of the chemotherapy.
Thus, the positive predictive value of a PET-2 was 90% and the negative predictive value
was 97%. The sensitivity, specificity and overall accuracy of PET-2 were 86%, 98% and
95%, respectively. The 2-year probability of failure-free survival for PET-2 negative and for
PET-2 positive patients was 96% and 6%, respectively (log rank test = 116.7, p<0.01).
Interpretation and Conclusions. 18F-FDG-PET scan performed after two courses of conven-
tional standard-dose chemotherapy in advanced-stage Hodgkin’s disease was able to pre-
dict treatment outcome in 103/108 (95%) of the patients.
Key words: early response, FDG-PET, Hodgkin's disease.
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py course and PET-2 was 11.6 days (5-32); the interval
between the end of the therapy (either chemotherapy
or radiotherapy) and PET-6 was never less than 50 days. 
Treatment 
Most patients (104/108) were treated with six courses
of ABVD; the other four patients were treated with six
courses of the COPP/EBV/CAD regimen. At the end of
chemotherapy 57 of the 108 patients had bulky medi-
astinal disease or an initial lesion with a diameter equal
to or greater than 5 cm; these patients were given consol-
idation involved-field (IF) radiotherapy with 36 or 30 Gy,
respectively. All patients were given the therapy pro-
grammed at baseline, and in no case did the result of the
early PET scan (PET-2) influence treatment. Only in the
case of clinical evidence of overt resistance to
chemotherapy or disease progression was salvage ther-
apy given; this consisted of high-dose chemotherapy
followed by autologous stem cell transplantation. 
Response criteria
Response to therapy was assessed according to the
criteria defined at the Cotswolds meeting:9 complete
remission (CR) was defined as the disappearance of all
clinical evidence of the disease and the normalization of
all laboratory values and radiological findings that had
been considered abnormal before therapy onset. An
unconfirmed CR (CRu) was defined as CR but with the
persistence of a residual lymph node mass greater than
1.5 cm that had regressed by more than 75% of the
largest dimension of each measurable anatomical site of
disease localization. Partial remission (PR) was defined
as a greater than 50% reduction of the largest dimen-
sion of each measurable anatomical site of disease local-
ization, for at least 1 month. Stable disease (SD) or non-
response (NR) was defined as less than PR but not pro-
gressive disease. Progressive disease (PD) was present
when there was a more than 50% increase from the
smallest size achieved in the largest anatomical diame-
ter of any previously identified abnormal node, or when
any new lesion appeared during therapy. Relapse was
defined as the appearance of any new lesion or an
increase in the size of the previously involved sites by
≥50%. Early and late relapse were defined as a relapse
occurring within or later than 6 months after having
achieved CR, respectively.
PET scan imaging
The patients enrolled in the study were staged and
treated in 11 Italian hematology institutions, while the
FDG-PET scans were performed in six PET centers. For
each patient three PET scans were performed at the
same PET center and with the same instrument. Scans
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Table 1. Patients' clinical details.
Parameter N. of patients Percentage (%)
Male/female 51/57 47/53
Stage
Stage IIA unfavorable 34 31
Stage IIB 24 22
Stage IIIA 15 14
Stage IIIB 13 12
Stage IVA 8 7
Stage IV B 14 13
Histology
Lymphocyte predominant 4 4
Nodular sclerosing 88 81
Mixed cellularity 13 12
Lymphocyte-depleted 3 3
Elevated ESR (> 40 mm/h) 65 60
Abnormal LDH (> 1× normal) 21 19
Anemia (Hb < 10.5 g/dL) 13 12
Leukocytosis (WBC > 15,000 µL) 19 18
Bulky disease (yes/no) 41/67 38/62
Extranodal site (yes/no) 30/78 28/72
International Prognostic Score
0 28 26
1 34 31
2 29 27
3 10 9
4 3 3
5 4 4
Chemotherapy regimen
ABVD×6 104 96
COPP/EBV/CAD 4 4
Figure 1. Trial overview.
staging at baseline: CT+PET
Early restaging: CT+PET
Consolidation: radiotherapy
Final restaging: CT+PET
PET-2
PET-6
PET-0
1st ABVD
6st ABVD
2st ABVD
Table 2. Characteristics of PET centers.
Equipment N. of  PET N. of Hematology N. of patients 
centers centers 
CT-PET 3 5 44
Multiring PET 1 1 30
C-PET 2 5 34
Advanced-stage HD
B
B
B
B
B
B
B
B
were performed with a GE Advance Nxi (multiring PET)
in one center, a Discovery LS CT-PET scanner (GE
Medical Systems, Milwaukee, WI, USA) operating in a
two-dimensional high sensitivity mode in two centers,
a Gemini CT-PET scanner operating in a three-dimen-
sional mode (Philips Electronics N.V., Eindhoven,
Netherlands) in one center and a full ring NaI(Tl)PET
scanner (C-PET ADAC, Philadelphia, PA,USA) in two
centers (Table 2). All patients fasted for at least 6 h
before injection of the 18F-FDG tracer. The serum glu-
cose level measured at the time of injection was below
160 mg/dL in all patients. Whole-body emission scans
were performed 60 min after injection. The injected
dose was 370 MBq/70 kg  at the centers which used a
GE scanner,  259 MBq/70 kg at the center which used a
Philips scanner and 2 MBq/kg body weight at the cen-
ters which used a C-PET scanner. Transmission scans
for segmented attenuation correction were acquired
with a germanium-68 or cesium-137 external ring
source or CT. To minimize the accumulation of FDG in
the bladder, patients were asked to void just before the
start of the emission scan. Transaxial, coronal and sagit-
tal images were reconstructed by means of the ordered
subsets-expectation method (OSEM) or the RAMLA
method. 
PET scan analysis
PET images were visually interpreted and analyzed
using all available clinical data and results of other imag-
ing modalities. All the positive or equivocal scans were
reviewed in each center by two experienced observers,
well trained with the equipment used in the same PET
center. For qualitative analysis, according to conventional
criteria, a study was considered positive for lymphoma
lesions in the presence of a focal concentration of FDG
outside the areas of physiological uptake, with a value
increased relative to the background. Before and after
therapy, disease was evaluated site by site for the
involved lymph nodes and organs. A negative result
was defined as no pathological FDG uptake at any site,
including all sites of previously increased pathological
uptake. For quantitative analysis of regional FDG
uptake in tumor, we calculated the SUV. Small, round,
(approximately 1 cm diameter) regions of interest (ROI)
were defined in the slice displaying the highest tumor
activity concentration, site by site. The SUVMax repre-
sents the maximum count density concentration record-
ed for each ROI normalized for the injected dose and
body weight. In the baseline PET scan the SUVMax was
measured in the lesion with the highest FDG uptake
among all the positive lesions. In the PET scan after two
cycles of chemotherapy (PET-2) and that at the end of
therapy (PET-6), in the case of persisting pathological
uptake of FDG in one or more lesions the SUVMax was
calculated in the lesion with the highest FDG uptake
and its value was correlated with the SUVMax of the same
lesion in the baseline study. When the hot lesions had
disappeared so that they were indistinguishable from
the surrounding normal tissue, no activity was meas-
ured and the patient was considered to have had a com-
plete metabolic response. 
Sample size 
The number of patients enrolled in this prospective
study was based on the following assumptions: to
detect an absolute difference of 65% in progression-free
survival (from 15% to 80% at 18 months) between PET-
2-positive and PET-2-negative patients, with 90%
power and using a significance level α=0.05 (two-sided),
17 patients per group would be needed. Because only
15% of HD patients are PET-2-positive and allowing
some loss during the follow-up, the first target was to
enroll 108 patients into the trial.
Statistical analysis
All data were analyzed with the SAS System 8.2 sta-
tistical package.10 Progression-free and failure-free sur-
vival rates were calculated from the date of diagnosis,
according to the method of Kaplan and Meier.11 Failure
was defined as partial remission, progression during
therapy, early or late relapse, treatment interruption due
to toxicity or toxic death. The association between clin-
ical prognostic factors and the probability of treatment
failure was assessed by the log-rank test.12 To control for
potential confounders, a multivariate analysis based on
a Cox proportional hazards regression model13 was per-
formed. The variables analyzed included all the factors
that were found to be significant in the univariate analy-
sis. For each variable, the proportional hazards assump-
tion was tested graphically. The exponentiation of the
coefficients estimated from the regression model can be
assumed as the hazard ratio of disease progression in
the category with each variable, compared with the ref-
erence category, after allowing for the other factors
entered in the model. Several Cox regression models
were fitted. The goodness-of-fit of each model was
assessed with the D statistic = -2, the likelihood ratio
and the comparison between two models, when feasi-
ble, was tested calculating the likelihood ratio.14 The
limit of statistical significance for all analyses was
defined as a p value of 0.05. All statistical tests were
two-sided.
Results
The mean follow-ups from the diagnosis and from
final restaging were 603 days (73-1421) and 359 days (0-
1148), respectively. Eighty-eight patients attained CR
while 20 were resistant to chemotherapy. Of these 20
patients, 16 had disease progression during therapy and
four had early relapses (within 6 months) after having
achieved CR: (+28 - +178 days). One out of the 88
patients who achieved CR had a late relapse 18 months
after CR. In all these cases a second biopsy confirmed
the histological diagnosis of HD. At the time of writing
only one out of 88 patients in CR has relapsed. No treat-
ment interruptions where necessary because of toxicity
and no toxic deaths occurred.
PET scan analysis
On qualitative analysis PET-2 was positive in 20
patients. Of these 20 patients, 13 progressed during
therapy and four relapsed within 6 months from having
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reached CR; these 17 patients all underwent salvage
therapy with high-dose chemotherapy and autologous
stem cell transplantation. Two other patients, showing
a progressive reduction of SUV in subsequent PET scans
up to complete negativity, remained in CR; one patient
had a late relapse 18 months after entering CR. By con-
trast, 85/88 (97%) patients with a negative PET-2 also
had a negative PET-6 and remained in CR. In one of the
two patients with a positive PET-2 the focal abnormali-
ty was in the same area involved in the baseline study,
while in the second patient the uptake was recorded in
the medial right pulmonary lobe, close to the focal area
involved at baseline (mediastinal nodes), but in a differ-
ent site. However, because a confirmatory biopsy could
not be obtained, the scan was considered a true posi-
tive. Three patients showed disease progression in spite
of having a negative PET-2. The clinical characteristics
of these patients were not dissimilar from those of the
overall population: one patient was in stage IIIA and
two in stage IVB while the Hasenclever score was 2 in
all three. The PET-2 scans were uniformly negative
without any focal FDG uptake (Figure 2). In all three
patients the PET-6 scan was positive. Two of these
patients were studied using a Discovery LS CT-PET
scanner and the third patient was studied using a
Gemini CT-PET scanner. 
On quantitative analysis, in the 20 patients with a PET-
2-positive scan, the mean percentage of the reduction of
SUVMax in PET-2 with respect to PET-0 was 39%. The
mean percentage of the SUVMax reduction in the 12
patients who progressed during therapy and in the five
patients who relapsed was 35% while for the two
patients with a PET-2-positive scan who remained in CR
the SUVMax reduction was 80% (p>0.05). For the 88
patients with PET-2-negative scans the SUVMax reduction
was 100%. CT-2 (performed in 97 patients.) showed PR in
92 patients and CR in five. The median International
Prognostic Score value of PET-2-positive patients was
higher than that of the PET-2-negative patients: 2.0 vs.
1.0, respectively (p<0.05).
Prognostic factors
In order to assess the risk of disease relapse or progres-
sion, for the univariate analysis we took into account the
clinical variables considered in the International
Prognostic Score (Table 3). Besides the PET-2 result
(p<0.01), the clinical factors that were significantly associ-
ated with a higher probability of treatment failure were
stage (p<0.01), International Prognostic Score (p< 0.01),
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Figure 2. PET-2 result and treatment outcome.
Table 3. Kaplan-Meier cumulative proportion of 2-year failure-free
survival (FFS) according to factors associated with a higher prob-
ability of progression. 
Variable Modality n Two-year probability of FFS Log –rank
(standard error) (p)
PET 2 Positive 20 0.06 (0.06) 116.7 (p<0.01)
Negative 88 0.96 (0.02)
Gender Male 51 0.68 (0.12) 0.4 (p>0.05)
Female 57 0.82 (0.05)
Stage II-III 86 0.86 (0.04) 21.2 (p<0.01)
IV 22 − (−)*
Age (years) ≤≤31 56 0.82 (0.07) 2.0 (p>0.05)
>31 52 0.74 (0.06)
International 0-1 62 0.89 (0.04) 6.8 (p<0.01)
Prognostic Score 2-5 46 0.59 (0.11)
ESR (mm/h) ≤ 40 43 0.87  (0.07) 4.8 (p<0.05)
> 40 65 0.72  (0.06)
LDH normal 87 0.82 (0.04) 1.2 (p>0.05)
abnormal 21 0.58 (0.16)
WBC (n /µL) ≤ 15000 89 0.83 (0.05) 9.7 (p<0.01)
> 15000 19 0.56 (0.12)
Hemoglobin ≥10.5 95 0.80 (0.05) 1.2 (p>0.05)
(g/dL) < 10.5 13 0.64 (0.15)
Bulky disease No 67 0.81 (0.06) 1.3 (p>0.05)
Yes 41 0.73 (0.08)
Extranodal sites No 78 0.87 (0.04) 8.0 (p<0.01)
Yes 30 0.54 (0.12)
*no patient reached 2-year follow-up.
Table 4. Factors significant in multivariate analysis from a Cox pro-
portional hazards regression analysis. Values are given as hazard
ratios with 95% confidence intervals.
Variable Modality n Hazard ratio 
(95% C.I.)
PET 2 Positive 20 55.5 (16.0-192.8)
Negative 88 1.0 
PEt-2 results and clinical outcome
Cytes l and 2 of ABVD
Cytes 3 to 6 of ABVD 3°-6°± radiotherapy 
PROGR PROGR
PET-2
positive
PET-2
negative
CR CRREL
108
20 88
17 2 1 85 3
PET-6 pos PET-6 posPET-6 neg PET-6 neg
haematologica/the hematology journal | 2006; 91(4) | 479 |
white cell count (p<0.01), erythrocyte sedimentation rate
(p< 0.05), and involvement of extra-nodal sites (p<0.01).
Since leukocytosis and stage are two clinical factors
included in the International Prognostic Score, only the
latter was considered for the multivariate analysis. The
only factor that turned out to have an independent prog-
nostic significance for relapse or progression in the multi-
variate analysis was a positive PET-2 scan, with a very
high hazard ratio (55.5; 95 % C.I. 16.0-192.8) (Table 4). In
terms of disease progression, the positive predictive value
of the PET-2 scan was 90% and the negative predictive
value was 97%. The sensitivity of PET-2 was 86%, the
specificity was 98% and the overall accuracy 95%. The 2-
year probabilities of failure-free and progression-free sur-
vival for PET-2-negative and for PET-2-positive patients
were 96% and 96% and 6% and 13%, respectively (fail-
ure-free survival log rank test = 116.7, p<0.01; progres-
sion-free survival log rank test=106.4, p<0.01: Figure 3). 
The positive predictive value of PET-6 was 92% and
the negative predictive value was 97%. The sensitivity
of PET-6 was 79%, the specificity was 99% and the
overall accuracy 96%.
Discussion
The optimal treatment for patients with advanced-
stage HD is still matter of debate. ABVD therapy is able
to offer long-term disease cure in about two-thirds of
patients and, according to most groups, it remains the
gold standard for randomized trials of advanced HD.15-17
Recently BEACOPP, a new dose-escalated and accelerat-
ed regimen, has shown superior disease control with an
updated 7-year failure free-survival of 85%,18 but at the
cost of a not trivial incidence of acute and late-onset side
effects.19 The authors claimed that this new intensified
regimen was so effective that there was no longer need
for prognostic indicators in HD.7
The current prognostic models are unable to support a
risk-adapted therapeutic strategy: they show low effica-
cy and a scarce predictive power.5 The most widely
accepted and well-known prognostic model is the
International Prognostic Score for advanced HD; in this
series, however, only 7% of patients with a score ≥5
(with very poor prognosis), and only 19% patients with
scores 4 and 5 had a less than 50% probability of pro-
gression-free survival at 7 years. The authors concluded
that there was no distinct group of patients that could be
identified as being at very high risk of disease progres-
sion.4 For these reasons new prognostic models, based
on specific biological characteristics of the tumor, such
as chemosensitivity20,21 or cytokine production,22,23 have
been proposed. The former was evaluated in 207 cases
of advanced-stage HD in the EORTC 1981-86 trial:
patients attaining the so-called early complete response
after four cycles of chemotherapy showed a 14-year
overall survival rate of 80% vs. 65% for patients without
an early complete response (p<0.01).24 More recently,
response was assessed in HD patients after one, two,
three, and four courses of chemotherapy by total body
67Ga-scans25 or 18F-FDG-PET scans in preliminary reports
in HD patients,26-29 and more extensively, in non-
Hodgkin’s lymphoma.30-32 In HD the sensitivity and
specificity of PET scanning performed after the first
cycle for predicting 18-month outcome were 82% and
92%, respectively, with an overall accuracy of 87%.26 In
the largest study published so far by Hutchings on 77
patients,29 FDG-PET was the most accurate parameter
for predicting progression-free survival; however, since
nearly two-thirds (63%) of the patients were in clinical
stage I-II, with a probability of cure of about 90%, the
prognostic role of PET in this group of patients was
overemphasized. The rationale for appraising the
response to chemotherapy so early during therapy lies in
the high sensitivity of PET scans in detecting the persist-
ence of potentially resistant clones responding to treat-
ment more slowly than chemosensitive tumor cells,
which might re-expand at the end of treatment and ulti-
mately cause disease progression.33 Several clinical trials
have indicated that quantification of the change in 18F-
FDG uptake may provide an early and sensitive pharma-
codynamic marker of antiblastic chemotherapy, and rec-
ommendations on 18F-FDG measurements of uptake
have been reported.34 Calculation of SUV has been con-
sidered the most suitable approach for measuring thera-
py-induced changes in tumor FDG uptake. In our popu-
lation, however, probably due to the high chemosensi-
tivity of Hodgkin’s neoplastic cells, most of the patients
had PET-2-negative scans, and therefore the evaluation
of the response based on a quantitative measure did not
offer any advantage over a qualitative evaluation. Only
20 out of our 108 patients had PET-2-positive scans and
most of these (18/20) were chemoresistant (mean SUV
reduction of 39%); in the two patients in continuous CR
the mean reduction of SUV was 80% (p>0.05). For this
reason we think that a larger study population is neces-
sary to demonstrate the utility of quantitative analysis in
the early evaluation of patients with a positive PET scan.
The main end-point of the study was the predictive
value of PET-2 for 2-year progression-fee survival. All
but one of the 20 failures recorded in the present study
(16 progressions and 4 early relapses) occurred within 6
months after achieving CR.
The mean follow-up in the present study (603 days),
although relatively short, was  longer than that needed
to define progression and not very different from the
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Figure 3. Probability of failure-free survival according to PET-2
results.
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follow-ups in other studies26,29 with the same end-point.
Secondly, in the present study we demonstrated the
high predictive value of PET-2 on overall treatment out-
come: the sensitivity, specificity and accuracy of PET-2
were 86%, 98% and 95%, respectively. The positive
predictive value was 90% and the negative predictive
value 97%; these results are very similar to those report-
ed by Kostakoglu.26
Thirdly, we confirmed the high chemosensitivity of
HD neoplastic cells. Indeed, only 20 out of 108 patients
(18.5%) had PET-2-positive scans: most of these (17/20)
showed disease progression or early relapse, with only
one showing a late relapse more than one year after
achieving CR suggesting that the PET-2-positive scan
was due to the persistence of chemoresistant clones.
However, since only a small fraction of patients had a
PET-2-positive scan (18.5%), very large series of PET-2-
positive patients must be monitored to confirm the
prognostic impact of an early positive scan. In any case,
our results appear relevant considering that this was a
multicenter trial and that different PET scanners were
used. While the results of the PET-2 scan reflect the
chemosensitivity of the cells to therapy, the result of the
PET-6 scan reflect the global effect of the therapy. The
prognostic information obtained at the end of therapy
was of the same magnitude as that observed by others.35
Finally, our data seem to indicate a strong prognostic
role for PET scans performed early during treatment.
The cohort of patients studied, although including a
small subset with unfavorable stage IIA disease, was
characterized by a high tumor burden and sub-optimal
treatment response, with a non-trivial risk of relapse of
30-35% at 10 years. For these reasons we explored,
besides early PET, other prognostically relevant clinical
variables for their value to predict treatment outcome,
such as International Prognostic Score, stage, erythro-
cyte sedimentation rate and white cell count. The fact
that the PET-2 scan emerged as the only significant fac-
tor in multivariate analysis confirms the relevance of
chemosensitivity as a prognostic factor strictly related
to the biology of the tumor, and independent of other
variables such as tumor burden.
The rationale of our study was to evaluate the predic-
tive value on treatment outcome of  PET performed
after two courses of ABVD in advanced-stage HD, in
order to identify patients primarily refractory to therapy
as early as possible. It is well known that these patients
have a worse outcome than patients who relapse early
or late after having achieved CR,36-37 and therefore they
should be treated with a different therapeutic strategy
and very aggressively from the onset of their disease.
Our data are in keeping with this concept: the 2-year
probability of failure-free survival for PET-2-negative
and PET-2-positive patients was 96% and 6%, respec-
tively (log rank test =116.7, p<0.01: Figure 3). These
results, together with Hutching’s data,29 seem robust
enough to unequivocally confirm the prognostic role of
PET-2 in the therapeutic strategy of advanced stage HD
and to prompt the design of new clinical trials in these
patients focused on early evaluation of chemosensitivi-
ty through FDG-PET scanning. The place of this prog-
nostic tool in the global therapeutic strategy for
advanced HD could be better defined, in PET-2-posi-
tive- patients, by randomized trials comparing standard
therapy with early chemotherapy intensification fol-
lowed by autologous stem cell transplantation, with an
unmodified therapeutic strategy.
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